Stuttgart
28.08.26 | 21:56
61,50 Euro
0,00 % 0,00
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 61,00 | 63,50 | 28.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Novonesis Expands U.S. Workforce Development Efforts to Build the Next Generation of Biomanufacturing Talent | 4 | GlobeNewswire (USA) | ||
| Di | Novonesis (Novozymes A/S): Trading by management and close relations of management | 4 | GlobeNewswire (USA) | ||
| Mo | Johnson & Johnson, Novozymes und mehr Dividenden im global market - Ex-Tag 25.08.2026 | 8 | Wiener Börse | ||
| 20.08. | Novonesis H1 2026 slides: 8% growth drives raised outlook, EUR 1B buyback | 5 | Investing.com | ||
| 20.08. | Novozymes Aktie steigt nach starken Zahlen, Prognoseerhöhung und Milliarden-Rückkaufprogramm | 9 | Investing.com Deutsch | ||
| 20.08. | Novozymes Reports H1 2026 Results: Full Earnings Call Transcript | 3 | Benzinga.com | ||
| 20.08. | Novozymes Q2 revenue up 9.8% Y/Y; raises FY26 organic sales growth outlook, inaugural €1B share buyback plan | 7 | Seeking Alpha | ||
| 20.08. | Novonesis Q2 Profit Rises | 510 | AFX News | BRUSSELS (dpa-AFX) - Novonesis (NVZMF.PK) released earnings for its second quarter that Increases, from the same period last yearThe company's bottom line came in at EUR171.7 million, or EUR0.37... ► Artikel lesen | |
| NOVONESIS A/S ADR Aktie jetzt für 0€ handeln | |||||
| 19.08. | Novonesis (Novozymes A/S): H1 2026: Novonesis delivered strong 8% organic sales growth and increases full-year outlook | 793 | GlobeNewswire (Europe) | COPENHAGEN, Denmark - August 19, 2026. Novonesis delivered strong first half of 2026 at 8% organic sales growth. 2026 outlook: Organic sales growth increased to 7-8% (previously 5-7%), and the adjusted... ► Artikel lesen | |
| 19.08. | Novonesis (Novozymes A/S): Interim report H1 2026 | 617 | GlobeNewswire (Europe) | Strong first half year at 8% organic sales growth. 2026 outlook: Organic sales growth increased to 7-8% and the adjusted EBITDA margin expected at the higher end of the 37-38% range. Inaugural share... ► Artikel lesen | |
| 19.08. | Novonesis (Novozymes A/S): Announcement of share buyback program | 450 | GlobeNewswire (Europe) | The Board of Directors of Novonesis has approved an inaugural multi-year share buyback program in a total amount of EUR 1 billion to be initiated during the second half of 2026 and expected to be... ► Artikel lesen | |
| 19.08. | Novonesis (Novozymes A/S): Increased outlook for 2026 | 416 | GlobeNewswire (Europe) | Novonesis increases its full year 2026 organic sales growth outlook from 5-7% to now 7-8% based on a stronger performance so far in the year and the expectations for the rest of the year. Following... ► Artikel lesen | |
| 12.08. | Novonesis (Novozymes A/S): Novonesis launches Optiva Triticum to help pasta manufacturers navigate wheat volatility without compromising quality | 301 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, August 12, 2026 - Novonesis today announced the launch of Optiva® Triticum, a new biosolution that helps pasta manufacturers increase flexibility in wheat sourcing while maintaining... ► Artikel lesen | |
| 10.08. | Novonesis To Acquire Remaining MicroBioGen Shares | 645 | AFX News | CANBERA (dpa-AFX) - Novozymes A/S (NSIS-B.CO), a manufacturer of industrial enzymes, functional proteins, and microorganisms, Monday announced that it has agreed to acquire the remaining shares... ► Artikel lesen | |
| 10.08. | Novonesis (Novozymes A/S): Novonesis to acquire remaining share of MicroBioGen to strengthen yeast capabilities | 1.584 | GlobeNewswire (Europe) | Novonesis to acquire remaining share of MicroBioGen to strengthen yeast capabilities
COPENHAGEN, Denmark, August 10 - Novonesis has signed an agreement with the intent to acquire MicroBioGen, an... ► Artikel lesen | |
| 03.07. | BNP Paribas stuft Novonesis nach 20 % Underperformance hoch | 26 | Investing.com Deutsch | ||
| 06.05. | Novonesis (Novozymes A/S): Trading by management and close relations of management | 41 | GlobeNewswire (USA) | ||
| 05.05. | Novozymes A/S reports Q1 results | 64 | Seeking Alpha | ||
| 05.05. | Novonesis Q1 2026 slides: 7% organic growth amid currency headwinds | 38 | Investing.com | ||
| 05.05. | Novonesis Q1 2026: Organisches Wachstum von 7 % trotz Währungsgegenwind | 26 | Investing.com Deutsch |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GENMAB | 289,00 | +1,01 % | Could Genmab (GMAB) Stock Win as Royalty Growth Fuels a New Earnings Cycle? | ||
| INSMED | 102,44 | +0,14 % | Insmed's BRINSUPRI Wins Japan Approval For Treatment Of Non-Cystic Fibrosis Bronchiectasis | WASHINGTON (dpa-AFX) - Monday, Insmed Inc. (INSM) announced that Japan's Ministry of Health, Labour and Welfare has approved BRINSUPRI, or brensocatib 25-mg tablet, for the treatment of non-cystic... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 13,730 | 0,00 % | Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy | ||
| BIONTECH | 88,30 | +0,11 % | BioNTech Aktie: Im Rausch der Moderna-Euphorie - Doch wie lange hält die Party an? | © Foto: von fernando zhiminaicela auf Pixabay (Symbolbild)Fast 30 Prozent in einer einzigen Woche. Das ist lange her, dass sowas bei BioNTech vorkam. Zuletzt wohl zu Pandemie-Zeiten ging es mal so zur... ► Artikel lesen | |
| QIAGEN | 37,590 | -0,42 % | QIAGEN ernennt Jonathan M. Pratt zum Vorstandschef | Bad Marienberg (www.anleihencheck.de) - QIAGEN N.V. ((ISIN NL0015001WM6/ WKN A41HBE; NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die Ernennung von Jonathan M. Pratt zum Vorstandsvorsitzenden... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 23,780 | 0,00 % | Here's Why You Should Add ARQT Stock to Your Portfolio Now | ||
| HARMONY BIOSCIENCES | 39,210 | 0,00 % | Wolfe Research initiates Harmony Biosciences stock at Outperform | ||
| ERASCA | 18,040 | +0,06 % | Erasca, Inc. - 8-K, Current Report | ||
| APOGEE THERAPEUTICS | 134,97 | 0,00 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,670 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| MODERNA | 119,06 | -0,03 % | Moderna explodiert 177 gelingt jetzt das große Comeback? | ||
| PRAXIS PRECISION MEDICINES | 345,01 | +0,08 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| RELAY THERAPEUTICS | 18,760 | -0,05 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 78,08 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| VERA THERAPEUTICS | 34,210 | +0,06 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen |
Das Unternehmen NOVONESIS A/S ADR kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 61,50 Euro und damit 0,00 % im Plus. Beim derzeitigen Kurs ergibt sich, basierend auf einer gesamten Ausschüttung von 0,00 Euro in den vergangenen 12 Monaten, eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NOVONESIS A/S ADR finden Sie auf Wallstreet Online.